• 支持MPN
Logo Logo
  • 调查
  • 意见与分析
  • 卡通
  • 播客
  • 视频
  • 语言
    • English
    • русский
    • Español
    • اَلْعَرَبِيَّةُ
    • Français
Former U.S. Marine Sgt. Ryan Begin smokes medical marijuana at his home in Belfast, Maine. Begin had endured 35 surgeries after having his right elbow blown off by a roadside bomb in 2004. He is a proponent of legalizing pot for recreational use and allowing individual citizens the right to grow six plants. (AP Photo/Robert F. Bukaty)

DEA Approves First-Ever Trial Of Medical Marijuana For PTSD In Vets

关注我们

  • Rokfin
  • Telegram
  • Rumble
  • Odysee
  • Facebook
  • Twitter
  • Instagram
  • YouTube
Former U.S. Marine Sgt. Ryan Begin smokes medical marijuana at his home in Belfast, Maine. Begin had endured 35 surgeries after having his right elbow blown off by a roadside bomb in 2004. He is a proponent of legalizing pot for recreational use and allowing individual citizens the right to grow six plants. (AP Photo/Robert F. Bukaty)
Former U.S. Marine Sgt. Ryan Begin smokes medical marijuana at his home in Belfast, Maine. Begin had endured 35 surgeries after having his right elbow blown off by a roadside bomb in 2004. He is a proponent of legalizing pot for recreational use and allowing individual citizens the right to grow six plants. (AP Photo/Robert F. Bukaty)

SANTA CRUZ – The U.S. Drug Enforcement Administration (DEA) has formally approved the first-ever randomized controlled trial of whole plant medical marijuana (cannabis) as a treatment for posttraumatic stress disorder (PTSD) in U.S. veterans. The DEA’s approval marks the first time a clinical trial intended to develop smoked botanical marijuana into a legal prescription drug has received full approval from U.S. regulatory agencies, including the DEA and the Food and Drug Administration (FDA).

The randomized, blinded, placebo-controlled study will test the safety and efficacy of botanical marijuana in 76 U.S. military veterans with treatment-resistant PTSD. The study is funded by a $2.156 million grant from the Colorado Department of Public Health and Environment (CDPHE) to the California-based non-profit Multidisciplinary Association for Psychedelic Studies (MAPS), which is sponsoring the research.

The trial will gather safety and efficacy data on four potencies of smoked marijuana with varying ratios of tetrahydrocannabinol (THC) and cannabidiol (CBD). By exploring the effectiveness of a variety of marijuana strains, the study seeks to generate naturalistic data comparable to how many veterans in medical marijuana states currently use marijuana. Results will provide vital information on marijuana dosing, composition, side effects, and areas of benefit to clinicians and legislators considering marijuana as a treatment for PTSD.

“We have been working towards approval since we opened the Investigational New Drug Application (IND) with the FDA in 2010,” says Amy Emerson, Executive Director and Director of Clinical Research for the MAPS Public Benefit Corporation. “We are thrilled to see this study overcome the hurdles of approval so we can begin gathering the data. This study is a critical step in moving our botanical drug development program forward at the federal level to gather information on the dosing, risks, and benefits of smoked marijuana for PTSD symptoms.”

Marcel Bonn-Miller, Ph.D., of the University of Pennsylvania’s Perelman School of Medicine, will oversee the two separate sites as Coordinating Principal Investigator (PI). Half of the subjects will be treated by Co-Investigator/Site PI Sue Sisley, M.D., in Phoenix, AZ, and the other half by Co-Investigator/Site PI Ryan Vandrey, Ph.D., at Johns Hopkins University in Baltimore, MD. Co-Investigator Paula Riggs, M.D., of the University of Colorado School of Medicine, will oversee the scientific integrity of the study. Blood analysis will be conducted at the University of Colorado, Boulder. MAPS will work with the FDA to manage and monitor data, oversee drug accountability, and ensure that the study follows Good Clinical Practice guidelines.

Since its founding in 1986, MAPS has raised over $36 million for psychedelic therapy and medical marijuana research and education. MAPS is working to evaluate the safety and efficacy of botanical marijuana as a prescription medicine for specific medical uses approved by the FDA.

Comments
22 4 月, 2016
Multidisciplinary Association For Psychedelic Studies

What’s Hot

膝盖骨与以色列游说团体:一支叛军如何震撼英国

从媒体宠儿到不受欢迎的人:格蕾塔·通贝里的心路历程

揭露:欧盟国家谴责加沙种族灭绝,秘密与以色列签署数十亿美元武器交易

英国巴勒斯坦团结运动官员承认与前以色列间谍合作

纳伊布·布克莱的萨尔瓦多独裁统治:以色列制造

  • 联系我们
  • Archives
  • About Us
  • 隐私政策
© 2025 MintPress News